Fizza Sajid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fizza Sajid has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abu Huraira Bin Gulzar
Department of Medicine Services Institute of Medical Sciences Lahore Pakistan
1 shared publication - Asad Ali Ahmed Cheema
Department of Medicine, International School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
1 shared publication - Deep Birjani
Dow University of Health Sciences, Karachi, Pakistan, Pakistan
1 shared publication - Eraj Nadeem
Liaquat National Medical College Karachi Pakistan
1 shared publication - Fnu Hamna
Fatima Jinnah Medical University Lahore Pakistan
1 shared publication - Hadia Haseeb Ahmad
Ivane Javakhishvili Tbilisi State University Tbilisi Georgia
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70446
Clinical Outcomes of Pulsed Field Vs. Thermal Ablation for Paroxysmal Atrial Fibrillation: Systematic Review and Meta‐Analysis of Randomized Evidence
Aims: Pulsed field ablation (PFA) is a non‐thermal alternative to conventional thermal ablation for paroxysmal atrial fibrillation (AF). We conducted an updated systematic review and meta‐analysis of randomized evidence comparing efficacy, safety, and procedural outcomes. Methods: PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials were searched from inception through March 2026 for randomized controlled trials (RCTs) comparing PFA with thermal ablation in adults undergoing first catheter ablation for paroxysmal AF. Risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Results: Four RCTs enrolling 1 393 patients were included. PFA showed no statistically detectable difference in 12‐month treatment success (RR, 1.04; 95% CI, 0.97 to 1.12; I 2 = 7%), recurrent atrial arrhythmias (RR, 1.00; 95% CI, 0.77 to 1.29; I 2 = 42%), or composite serious adverse events (RR, 0.71; 95% CI, 0.32 to 1.57; I 2 = 7%). PFA shortened procedure time (MD, −22.42 min; 95% CI, −33.44 to −11.39; I 2 = 91%) and LA dwell time (MD, −25.73 min; 95% CI, −34.66 to −16.79; I 2 = 92%), but increased fluoroscopy time (MD, 7.34 min; 95% CI, 0.39 to 14.30; I 2 = 98%). Conclusions: Across the included trial configurations, 12‐month efficacy estimates did not differ detectably. Sparse safety events and wide confidence intervals precluded equivalence claims. Pooled procedure and LA dwell times favored PFA, but platform, comparator, and workflow heterogeneity limit generalizability. Procedural findings are exploratory and should not be interpreted as direct energy‐specific effects.
- 20 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70446
Open AccessClinical Outcomes of Pulsed Field Vs. Thermal Ablation for Paroxysmal Atrial Fibrillation: Systematic Review and Meta‐Analysis of Randomized Evidence
Aims: Pulsed field ablation (PFA) is a non‐thermal alternative to conventional thermal ablation for paroxysmal atrial fibrillation (AF). We conducted an updated systematic review and meta‐analysis of randomized evidence comparing efficacy, safety, and procedural outcomes. Methods: PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials were searched from inception through March 2026 for randomized controlled trials (RCTs) comparing PFA with thermal ablation in adults undergoing first catheter ablation for paroxysmal AF. Risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Results: Four RCTs enrolling 1 393 patients were included. PFA showed no statistically detectable difference in 12‐month treatment success (RR, 1.04; 95% CI, 0.97 to 1.12; I 2 = 7%), recurrent atrial arrhythmias (RR, 1.00; 95% CI, 0.77 to 1.29; I 2 = 42%), or composite serious adverse events (RR, 0.71; 95% CI, 0.32 to 1.57; I 2 = 7%). PFA shortened procedure time (MD, −22.42 min; 95% CI, −33.44 to −11.39; I 2 = 91%) and LA dwell time (MD, −25.73 min; 95% CI, −34.66 to −16.79; I 2 = 92%), but increased fluoroscopy time (MD, 7.34 min; 95% CI, 0.39 to 14.30; I 2 = 98%). Conclusions: Across the included trial configurations, 12‐month efficacy estimates did not differ detectably. Sparse safety events and wide confidence intervals precluded equivalence claims. Pooled procedure and LA dwell times favored PFA, but platform, comparator, and workflow heterogeneity limit generalizability. Procedural findings are exploratory and should not be interpreted as direct energy‐specific effects.